Completed PHASE1 INTERVENTIONAL 4-arm NCT00873561

A Study to Evaluate NBI-6024 in Adult and Adolescent Patients With New Onset of Type 1 Diabetes Mellitus

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel, Dose-Ranging Study to Evaluate The Efficacy, Safety, Tolerability, and Pharmacodynamics of NBI-6024 In Adult and Adolescent Patients With New Onset Type 1 Diabetes Mellitus

Sponsor: Neurocrine Biosciences

Conditions Type 1 Diabetes Mellitus

Interventions NBI-6024

Updated 6 times since 2017 Last updated: Mar 30, 2009 Started: Dec 31, 2001 Primary completion: Apr 30, 2006 Completion: Jul 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Type 1 Diabetes Mellitus and is currently completed. Neurocrine Biosciences leads this study, which shows 6 recorded versions since 2001 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Dec 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Neurocrine Biosciences

Data source: Neurocrine Biosciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Cape Town, South Africa , Cruces-Baracado, Spain , Dundee, United Kingdom , Durban, South Africa , Hanover, Germany , Helsinki, Finland , Johannesburg, South Africa , KwaZulu Natal, South Africa , Laval, Canada and 10 more locations